As a new type of genetic testing technology, Gene Sequencing analyzes and tests complete gene sequencing through blood or ptysma which can forecast the possibility of personal diseases and different kinds of behavioral characteristics. Due to the reason of that it can lock the personal lesion gene, gene sequencing become an entrance of precision medical care which was regarded as “the next world-changing technology”.

NGS has already become a mainstream technology in modern time to consider Solexa and HiSeq under Illumina as the representatives. This tech extremely lowered the sequencing cost and increased the speed meanwhile maintained high precision. According to Illumina` s official website, its product, HiSeq X Ten consists from 10 ultrahigh throughput sequenators which can complete sequencing over 18,000 piece each year with only $1,000 cost per genome which is the first sequencing platform breaking through $1,000 cost in global.

Technology leaping pushes the gene detection sharply decrease which can pave the road for gene testing commercialization. In recent years, Illumina participated several significant gene projects globally. Last year, UK Department of Health chose Illuminaqixia embranchment as the “preferred partner” joining 100,000 people of complete genetic sequencing project held by UK government to obtain the genome information which will be applied to the treatment and research for cancer, rare disease and genetic disease. In addition, Illumina supplies gene sequencing equipment for medical center and human gene and laboratory diagnostic center including Laboratory Corp of American Holdings, Amgen, Quest diagnosis and Biomnis, Genoma located in Europe.

Illumina speeded up to matching Chinese market. Last week, it reached an agreement with Novogene to jointly develop the NGS platform applying to reproductive health and tumor. Before that, it has already established cooperation with BerryGenomics and Anoroda respectively in last May and June in this year. Illumina senior management shows that, in the world range Chinese market has been set to the core position because of its huge scale of gene sequencing market, at present it ranks only second to US, but possible to exceed the United States in the near future.